Valeo Financial Advisors LLC Sells 1,001 Shares of Hims & Hers Health, Inc. $HIMS

Valeo Financial Advisors LLC decreased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 14.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,161 shares of the company’s stock after selling 1,001 shares during the quarter. Valeo Financial Advisors LLC’s holdings in Hims & Hers Health were worth $307,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of HIMS. Smartleaf Asset Management LLC boosted its position in Hims & Hers Health by 15.7% in the first quarter. Smartleaf Asset Management LLC now owns 1,672 shares of the company’s stock worth $49,000 after purchasing an additional 227 shares during the last quarter. Allworth Financial LP boosted its position in Hims & Hers Health by 20.0% in the first quarter. Allworth Financial LP now owns 2,006 shares of the company’s stock worth $56,000 after purchasing an additional 334 shares during the last quarter. Signaturefd LLC boosted its position in Hims & Hers Health by 17.7% in the first quarter. Signaturefd LLC now owns 2,586 shares of the company’s stock worth $76,000 after purchasing an additional 388 shares during the last quarter. Kilter Group LLC boosted its position in Hims & Hers Health by 1.0% in the first quarter. Kilter Group LLC now owns 43,989 shares of the company’s stock worth $1,300,000 after purchasing an additional 450 shares during the last quarter. Finally, Larson Financial Group LLC boosted its position in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after purchasing an additional 458 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Hims & Hers Health in a research report on Tuesday, August 5th. Truist Financial dropped their price target on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research report on Monday, August 18th. Wall Street Zen lowered Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Saturday, September 27th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Hims & Hers Health has an average rating of “Reduce” and an average price target of $38.92.

Hims & Hers Health Stock Performance

Shares of HIMS opened at $58.13 on Friday. The stock’s 50-day simple moving average is $51.03 and its 200 day simple moving average is $47.78. The stock has a market capitalization of $13.14 billion, a price-to-earnings ratio of 72.67, a price-to-earnings-growth ratio of 3.93 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98. Hims & Hers Health, Inc. has a 52-week low of $17.36 and a 52-week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The company had revenue of $544.83 million for the quarter, compared to analysts’ expectations of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business’s revenue for the quarter was up 72.6% on a year-over-year basis. During the same period last year, the company posted $0.06 EPS. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Buying and Selling at Hims & Hers Health

In related news, insider Michael Chi sold 2,100 shares of the stock in a transaction dated Wednesday, September 24th. The stock was sold at an average price of $56.52, for a total transaction of $118,692.00. Following the sale, the insider owned 291,439 shares of the company’s stock, valued at approximately $16,472,132.28. This represents a 0.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Irene Becklund sold 8,410 shares of the stock in a transaction dated Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $424,705.00. Following the sale, the insider directly owned 1,418 shares in the company, valued at $71,609. This trade represents a 85.57% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,622,741 shares of company stock worth $83,695,469 in the last three months. 13.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.